ArticlePloS one2026
The neural transdifferentiation potential of bone marrow mesenchymal stem cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by demyelination and neuronal degeneration. Currently, there is no treatment that can promote remyelination or axonal repair and thus improve patient outcomes. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach in multiple sclerosis due to their regenerative and immunomodulatory properties. Priming MSCs toward neural- or glial-like cells may enhance their therapeutic potential.
methodsBone marrow MSCs from multiple sclerosis patients were cultured in differentiation medium containing growth factors for induction of glial and neural transdifferentiating process. Functional assays were used to characterize the proliferation and migration rates of undifferentiated and transdifferentiating MSCs. In addition, immunostaining with five different markers was performed as well as mass spectrometry to investigate and compare protein expressions among the cell types.
resultsProliferation and migration rates of MSCs decreased in glial and neural transdifferentiating cells. The immunostaining showed expression of neuro-glial markers, and the mass spectrometry data demonstrated substantial variance in protein expression in transdifferentiating MSCs compared to undifferentiated MSCs. Glial and neural markers were upregulated in the transdifferentiating MSCs, while MSC markers were downregulated.
conclusionThe results demonstrate that MSCs can be guided toward a neuro-glial lineage in vitro and that the transdifferentiating process continues over several weeks. Future research should investigate the in vitro and in vivo therapeutic differences between different transdifferentiating lengths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.